Vall D'hebron Institute Of Oncology

This trial is testing whether giving tarlatamab before and after surgery is safe and feasible for people with recurrent high-grade glioma, an aggressive brain cancer. Participants receive tarlatamab infusions before their tumor is removed, then continue treatment after surgery. T…

This Phase 2 trial is testing whether rilvegostomig, an experimental immunotherapy that blocks two immune-suppressing pathways (PD-1 and TIGIT), can produce a stronger immune response against advanced gastric cancer than the standard single-target drug pembrolizumab. About 50 peo…

This study tests whether giving a combination of three drugs (pembrolizumab, belzutifan, and lenvatinib) before surgery can shrink kidney tumors in people with localized clear cell renal cell carcinoma. About 150 participants will receive the drugs for 12 weeks before surgery, th…

This phase 2 trial is testing whether giving the drugs encorafenib and cetuximab again can help people with a specific type of advanced colorectal cancer (BRAF V600E-mutant) whose disease got worse after prior treatment with similar drugs. About 25 participants will receive the d…